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Abstract
In synucleinopathies, including Parkinson’s disease, partially ubiquitylated a-synuclein species phosphorylated on serine 129
(PS129-a-synuclein) accumulate abnormally. Parkin, an ubiquitin-protein ligase that is dysfunctional in autosomal recessive
parkinsonism, protects against a-synuclein-mediated toxicity in various models. We analyzed the effects of Parkin
deficiency in a mouse model of synucleinopathy to explore the possibility that Parkin and a-synuclein act in the same
biochemical pathway. Whether or not Parkin was present, these mice developed an age-dependent neurodegenerative
disorder preceded by a progressive decline in performance in tasks predictive of sensorimotor dysfunction. The symptoms
were accompanied by the deposition of PS129-a-synuclein but not PS87-a-synuclein in neuronal cell bodies and neuritic
processes throughout the brainstem and the spinal cord; activation of caspase 9 was observed in 5% of the PS129-a-
synuclein-positive neurons. As in Lewy bodies, ubiquitin-immunoreactivity, albeit less abundant, was invariably co-localized
with PS129-a-synuclein. During late disease stages, the disease-specific neuropathological features revealed by ubiquitin-
and PS129-a-synuclein-specific antibodies were similar in mice with or without Parkin. However, the proportion of PS129-a-
synuclein-immunoreactive neuronal cell bodies and neurites co-stained for ubiquitin was lower in the absence than in the
presence of Parkin, suggesting less advanced synucleinopathy. Moreover, sensorimotor impairment and manifestation of
the neurodegenerative phenotype due to overproduction of human a-synuclein were significantly delayed in Parkin-
deficient mice. These findings raise the possibility that effective compensatory mechanisms modulate the phenotypic
expression of disease in parkin-related parkinsonism.
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Introduction
a-Synuclein- and ubiquitin-immunoreactive protein inclusions
in neuronal cell bodies and processes (Lewy bodies, LBs; Lewy
neurites) or in glial cells are pathological markers of a subset of
neurodegenerative diseases referred to as synucleinopathies; these
diseases include Parkinson’s disease (PD), dementia with LBs and
other LB diseases, and multiple system atrophy. Phosphorylation
of serine 129 is a widespread a-synuclein modification in LBs,
whereas serine 87, found to be constitutively phosphorylated in
cell lines, is not modified in these inclusions [1,2]. A fraction of a-
synuclein is covalently modified by one to three ubiquitin
molecules in these inclusions [2–4]; there is biochemical evidence
that a-synuclein phosphorylated on serine 129 (PS129-a-synuclein)
is the major substrate for ubiquitylation [2]. Three rare missense
mutations in the a-synuclein gene, SCNA, and more frequently
duplications or triplications of genomic regions including SCNA
are responsible for parkinsonism with autosomal dominant
inheritance [5]. The severity of the phenotype correlates with
the number of SCNA copies in patients with genomic multiplica-
tions [6,7], and supernumerary SCNA alleles are associated with
increased protein load in both the blood and brain of affected
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individuals [8]. Thus, the pathogenesis of these familial parkinso-
nian syndromes appears to be a consequence of the overproduc-
tion of normal a-synuclein.
Overproduction of normal or mutated a-synuclein in inverte-
brate and rodent models leads to synucleinopathy and neurode-
generation [9–14]. Mice transgenic for human A30P or A53T a-
synuclein develop adult-onset neurodegenerative disorders leading
to progressive paralysis due to pathological alterations in
brainstem and spinal cord neuronal cell bodies or axons,
concomitant with the deposition of a-synuclein- and ubiquitin-
immunoreactive material throughout these regions [9,10,14,15].
Despite these striking parallels with human synucleinopathies, the
molecular mechanisms underlying a-synuclein toxicity remain
unclear. a-Synuclein aggregation in vitro is a multi-step process
involving the formation of oligomers, protofibrils and insoluble
amyloid fibrils [16]. How, and in which order, this process is
modulated in vivo by phosphorylation, ubiquitylation and possibly
other modifications is not known, and there is debate concerning
the contributions of the various molecular species to neurodegen-
eration.
Parkin is an E3 ubiquitin-protein ligase that is abnormal in
many cases of autosomal recessive parkinsonism [17]. Carriers of
parkin mutations have a more favourable disease course compared
to sporadic PD patients: although onset is generally earlier, disease
progression is significantly slower and the response to dopaminer-
gic treatment better than in sporadic PD [18,19]. Loss of Parkin
function, due to disease-causing parkin mutations, may impair
proteasomal degradation of toxic substrates, but may also
compromise non-proteolytic ubiquitin-dependent pathways relat-
ed to protein aggregation, protein sorting or cell signalling [20–
26]; partial loss of Parkin function, through age-related or
pathological alterations in its biochemical properties, may also
contribute to neurodegeneration associated with sporadic PD and
possibly other synucleinopathies [27–29]. Whether a-synuclein
plays a role in parkin-related parkinsonism is unclear. Of eight PD
cases with homozygous or compound heterozygous parkin
mutations analyzed post mortem, only three had typical LBs and
even here in small numbers, and only one had basophilic a-
synuclein-immunopositive dendritic inclusions [30]. Although
native a-synuclein is not a Parkin substrate [31], overproduction
of Parkin provided protection in a variety of models associated
with the short-term accumulation of a-synuclein, suggesting that
these proteins are functionally linked [32–35]. We explored this
possibility further, by evaluating the effects of Parkin deficiency in
transgenic mice producing human A30P a-synuclein under the
control of the Thy1 promoter (hA30Pa-syn mice). These mice
develop a-synuclein-dependent neurodegeneration over a mean
period of twenty months. Surprisingly, Parkin deficiency signifi-
cantly retarded disease manifestation in this model. These findings
suggest that loss of Parkin function may act as a beneficial modifier
of a-synucleinopathy in slowly progressing parkin-related parkin-
sonian syndromes.
Results
Parkin-deficiency delays progression of the
neurodegenerative phenotype in transgenic hA30Pa-syn
mice
A mouse model transgenic for human A30P a-synuclein and
deficient for Parkin was generated through a breeding strategy
aimed at minimising strain effects, using two previously established
mouse lines: parkin exon 3-deleted mice (parkin 2/2) [36] and
hA30Pa-syn mice [14,37] (Figure 1A). Homozygous parkin 2/2
mice were bred with homozygous hA30Pa-syn mice. The double
heterozygous generation was intercrossed to generate littermates of
the nine expected genotypes in proportions consistent with
Mendelian inheritance. Double homozygous mice and their age-
matched littermates of wild-type or single homozygous, parental
genotypes were kept for subsequent analyses. Appropriate
expression of the endogenous parkin gene and the a-synuclein
transgene were confirmed by western blotting with whole brain
extracts (Figure 1B).
As expected, adult transgenic hA30Pa-syn mice with or without
Parkin developed a neurodegenerative phenotype with age-dependent
penetrance, characterized by rapidly deteriorating motor performance,
resulting in paralysis of the hindlimbs within approximately one month
of the appearance of the first observable clinical signs (unsteady gait,
hindlimb weakness and dragging) [14]. These symptoms developed in
the absence of degeneration of the nigral dopaminergic neurons [14]
(Results S1, Figure S2 and Table S1), a neuronal population in which
human a-synuclein was not detected by immunohistochemistry
(Results S1, Figure S1B). We investigated whether Parkin deficiency
Figure 1. Generation of mice overproducing human a-synu-
clein in a Parkin-deficient background. (A) Breeding strategy.
Parental homozygous parkin 2/2 and hA30Pa-syn +/+ mice were
intercrossed. The breeding of the double heterozygous mice (F1) led to
the generation of littermates of the nine expected genotypes, four of
which, highlighted by the surrounding frames, were used for
subsequent analyses. (B) Representative western blot analysis of brain
extracts of 17 months-old mice showing the expression of the
endogenous parkin gene and of the hA30Pa-syn transgene, normalized
to actin levels.
doi:10.1371/journal.pone.0006629.g001
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affected the incidence and the progression of this neurodegenerative
phenotype: hA30Pa-syn mice with or without a functional parkin gene
and their littermates of wild-type and parental genotypes were followed
from 9months of age until death to unravel potential disease-predictive
changes in motor function (Figure 2). Every week, we tested the
hindlimb extension reflex, which is altered by motor neuron diseases
[38], and performance on a rotarod, which is progressively impaired in
hA30Pa-syn mice [39]. The mean performance in each task was
plotted against age for each genotype and the trends were analysed
using a second order polynomial curve fit (Figure 2A). The mean
performance of wild-type and parkin 2/2 mice in both tasks was
similar and remained constant throughout the testing period; in
contrast, a progressive, disease-predictive decline in performance was
observed in hA30Pa-syn mice. In addition, the decline in performance
of both tasks was significantly delayed in the absence of Parkin
(Figure 2A).
Consistent with delayed motor impairment in parkin 2/2 mice,
the manifestation of the neurodegenerative disorder caused by
overproduction of human a-synuclein – here defined as the
inability to perform the rotarod task (performance = 0) – was
significantly retarded in the absence of Parkin, as illustrated by
Kaplan-Meier curves representing the age-dependent penetrance
of disease in hA30Pa-syn mice (Figure 2B).
Accumulation of ubiquitin and PS129-a-synuclein but not
PS87-a-synuclein is associated with disease in hA30Pa-syn
transgenic mice
We assayed total human a-synuclein, PS129-a-synuclein and
PS87-a-synuclein in aged healthy and end-stage symptomatic
hA30Pa-syn mice with and without Parkin with antibodies
recognizing specifically each of these proteins (Figure 3A). Total
human a-synuclein was found in the buffer-soluble (TBS) and -
insoluble (SDS) brain fractions (Figure 3B, upper panel); it was for
the most part soluble and its relative solubility did not change with
the appearance of symptoms and was similar in the presence and
absence of Parkin (Figure 3C). PS87-a-synuclein was only found in
the TBS fraction, and the amounts found were similar for healthy
and symptomatic mice with or without Parkin (Figure 3B, middle
panel, Figure 3C). Most PS129-a-synuclein in healthy mice was
soluble, with approximately 10% of the protein being buffer-
insoluble, both in the presence and absence of Parkin (Figure 3B,
lower panel, Figure 3C). In contrast, insoluble PS129-a-synuclein
species accumulated in symptomatic mice, with approximately
60% of the protein found in the SDS fraction whether Parkin was
present or not (p,0.001 between symptomatic and non
symptomatic mice). In this fraction, long exposure times revealed
variable amounts of PS129-a-synuclein species with retarded
electrophoretic mobilities only in symptomatic mice (Figure 3D
and E). Soluble Parkin was readily detected in the TBS fractions
from healthy and symptomatic hA30Pa-syn mice with a functional
parkin gene. In contrast, it was not observed in the SDS fractions
even after long exposure times (Figure 3F).
We used immunohistochemistry to study the regional distribu-
tion of total human a-synuclein, PS129-a-synuclein, PS87-a-
synuclein and ubiquitin in the central nervous system of aged
healthy and end-stage symptomatic mice with and without Parkin.
Similar distributions were found for total human a-synuclein in the
presence and absence of Parkin, whether the animals had
symptoms or not (Results S1, Figure S1A). PS87-a-synuclein
immunoreactivity was undetectable in any of the conditions
studied (data not shown). In contrast, there was extensive PS129-a-
synuclein immunoreactivity in various regions of the brainstem
and the spinal cord in end-stage symptomatic hA30Pa-syn mice
with or without Parkin, but not in their non symptomatic
littermates (Figure 4A, B and Figure 5A, B). The extent of the
PS129-a-synuclein pathology was variable between animals but was
similar in the presence or absence of Parkin (Figure 4B). End-stage
symptomatic hA30Pa-syn mice but not their healthy littermates
also displayed variable severity of ubiquitin pathology (Figures 4C
and 5B). The regional distribution of ubiquitin overlapped with
that of PS129-a-synuclein, but was generally less extensive; it was
observed regardless of the parkin genotype.
Parkin deficiency mitigates ubiquitin pathology in
hA30Pa-syn transgenic mice
Staining for PS129-a-synuclein and for ubiquitin in end-stage
symptomatic hA30Pa-syn mice with and without Parkin appeared
in thin, tortuous, often short neuritic extensions; in hypertrophied,
Figure 2. Progression of the neurodegenerative phenotype is
delayed by Parkin deficiency in hA30Pa-syn mice. (A) Motor
function was assessed by evaluating the hindlimb extension reflex
(upper graph) and rotarod performance (lower graph). Mean perfor-
mance is plotted against age for each genotype and the curvature and
slope of parabolic regressions were analysed statistically (n = 10–16). #,
slope and curvature different from wild-type and parkin 2/2 with
p,0.0001; *, different curvatures with p,0.05. (B) Age-dependent
penetrance of the neurodegenerative phenotype in hA30Pa-syn mice
with or without Parkin (n = 12–14). *, p,0.01 (Kaplan-Meier analysis).
doi:10.1371/journal.pone.0006629.g002
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Figure 3. The solubility of PS129-a-synuclein but not PS87-a-synuclein species is decreased in the brains of end-stage symptomatic
hA30Pa-syn mice. (A) Representative western blot using protein-specific antibodies illustrating recognition of human a-synuclein and its isoforms
phosphorylated at serine 87 or 129, in the TBS-soluble brain fraction of a symptomatic transgenic hA30Pa-syn mouse. These proteins were not detected
in the TBS- or SDS-soluble brain fractions of an aged wild-type control animal (left panel). The anti-PS87- and anti-PS129-a-synuclein antibodies detected
specifically normal recombinant a-synuclein (PS87,129a-syn), phosphorylated in vitro by casein kinase 1 as described previously [42], but not the non
phosphorylated protein (a-syn). As expected, the anti-PS87-a-synuclein antibody also recognized the in vitro-phosphorylated S129A a-synuclein variant
(S129A PS87a-syn), but not phosphorylated S87A a-synuclein (S87A PS129a-syn). In contrast, the anti-PS129-a-synuclein antibody recognized S87A PS129a-
syn but not S129A PS87a-syn. (B) Representative western blots illustrating a-synuclein (top panel), PS87-a-synuclein and PS129-a-synuclein (middle and
bottom panels) protein abundance in TBS-soluble and -insoluble (SDS) brain fractions from symptomatic (S) and non symptomatic (ns) mice with and
without Parkin. (C) Quantitative analysis of human a-synuclein, PS87-a-synuclein and PS129-a-synuclein solubility in symptomatic and non symptomatic
hA30Pa-syn mice with (ns: n = 4; S: n = 1328) and without (ns: n = 4; S: n = 1128) Parkin. The relative protein amount was defined as the ratio between
the amount of protein normalized to a-tubulin in the SDS fraction, and the total amount of protein normalized to -tubulin in the SDS and TBS fractions.
The abundance of PS129-a-synuclein in the SDS brain fraction was significantly higher in symptomatic mice in the presence or absence of Parkin than in
healthy mice. *, p,0.01. (D) Representative western blots showing PS129-a-synuclein immunoreactive species with retarded electrophoretic mobility
after long exposure times in the SDS fraction from symptomatic mice. (E) Quantitative analysis of the monomer (short exposure times) and the PS129-a-
synuclein species with higher apparent molecular mass (long exposure times) in symptomatic mice with (n= 13) and without (n=11) Parkin. (F) Western
blot analysis with anti-Parkin antibodies of TBS and SDS fractions from a wild-typemouse, a representative pool of healthy and symptomatic hA30Pa-syn
mice, and a symptomatic Parkin-deficient hA30Pa-syn control mouse. Parkin was abundant in the TBS fractions but was not detected in the SDS fractions
from healthy or symptomatic mice, even after long exposure times. The asterisk indicates a non specific band recognized by anti-Parkin antibodies.
doi:10.1371/journal.pone.0006629.g003
PARK2 Modifies Synucleinopathy
PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6629
Figure 4. Distribution of PS129-a-synuclein- and ubiquitin-immunolabelling in symptomatic hA30Pa-syn mice. (A) Schematic illustration of
the distribution and density of PS129-a-synuclein deposits on representative brain coronal sections of symptomatic mice. Similar distributions were observed
in hA30Pa-synmice with or without Parkin. Regions immunolabelled in most animals are indicated in red, whereas those less frequently stained are in grey.
(B) Representative micrographs illustrating PS129-a-synuclein-immunolabelling in the brainstem (bregma22.9) of symptomatic hA30Pa-syn mice with and
without Parkin, and in a healthy hA30Pa-syn control mouse. Quantitative analysis of the density of PS129-a-synuclein-labelling in a representative region of
the brainstem of symptomatic mice (n=5 per genotype). (C) Representative micrographs illustrating typical ubiquitin-immunoreactivity in the presence or
absence of Parkin in the brainstem of symptomatic mice, and of a healthy hA30Pa-syn control mouse. 1- superior colliculus, 2- pretectal nuclei, 3- geniculate
nuclei, 4- periaqueductal grey layer, 5- zona incerta, 6- ventral tegmental area, 7- SN pars reticulata, 8- cerebellar white layer, 9- lateral cerebellar nuclei, 10-
vestibular nuclei, 11- cochlear nuclei 12- trigeminal nuclei, 13- pontine reticular nuclei, 14- parvicellular reticular nuclei. Scale bars indicate 200 mm.
doi:10.1371/journal.pone.0006629.g004
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spherical or elongated neuritic profiles; throughout the somato-
dendritic compartment; and, only rarely, in compact cytoplasmic,
nuclear or neuritic inclusions (Figure 5A). The relative frequencies
of these qualitatively different categories of labelled structures
differed between animals, but they were observed in mice of both
genotypes at disease end-stage; in the presence of Parkin,
aberrantly swollen neuritic profiles filled with PS129-a-synuclein-
and ubiquitin-immunoreactive material tended to be more
abundant that in its absence, as illustrated on spinal cord sections
from representative animals (Figure 5B).
We determined whether the ubiquitin staining observed in
diseased hA30Pa-syn mice was associated with the deposited
PS129-a-synuclein species by double fluorescent immunolabelling
of representative brain and spinal cord sections and confocal
microscopy (Figure 6A, top panel). Most of the ubiquitin staining
co-localized with PS129-a-synuclein staining (Pearson’s colocaliza-
tion coefficient = 0.8 in the presence and absence of Parkin).
Approximately 85% of the cell bodies and 55% of the neurites
immunopositive for PS129-a-synuclein were co-labelled with anti-
ubiquitin antibodies in transgenic hA30Pa-syn mice with Parkin
(Figure 6B); in mice deficient for Parkin, only approximately 50%
of the cell bodies and 35% of the neurites containing PS129-a-
synuclein immunopositive material were also ubiquitin-positive.
However, more than 90% of the pathologically swollen PS129-a-
synuclein-positive neurites were co-labelled for ubiquitin, whether
Parkin was present or not (Figure 6A, top panel). Immunoreac-
tivity to synphilin-1, a Parkin substrate reported to co-localize with
PS129-a-synuclein-positive inclusions when overproduced together
with a-synuclein in cell models [20], was not associated with PS129-
a-synuclein-positive protein deposits (Figure 6A, middle and
bottom panels).
We used GST pull down and in vitro ubiquitylation assays to test
whether Parkin interacts directly with and ubiquitylates phos-
phorylated a-synuclein. GST-Parkin interacted with the Parkin
Figure 5. Parkin deficiency mitigates neuritic pathology in end-stage symptomatic hA30Pa-syn mice. (A) Representative micrographs
illustrating PS129-a-synuclein and ubiquitin immunoreactivities in the brainstem of hA30Pa-syn symptomatic mice. Swollen, spherical (black
arrowheads) and elongated (black arrows) neuritic profiles, thin, thread-like neurites (white arrowhead), rare compact inclusions (white arrow), and
immunostaining throughout the somatodendritic compartment (stars) were observed. The two upper right micrographs correspond to a higher
magnification of the regions outlined by the frames in the left micrograph. Scale bars indicate 20 mm. (B) Representative micrographs illustrating
PS129-a-synuclein and ubiquitin immunoreactivities in the grey matter of the cervical spinal cord from hA30Pa-syn mice with (left column) and
without Parkin (right column). Note the abundance of aberrantly swollen neuritic processes (white arrows) in the presence of Parkin. Scale bar
indicates 60 mm.
doi:10.1371/journal.pone.0006629.g005
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Figure 6. The frequency of PS129-a-synuclein-positive structures immunolabelled with anti-ubiquitin antibodies is lower in the
absence than presence of Parkin. (A) Confocal scanning laser micrographs of a brainstem section from a representative symptomatic hA30Pa-syn
mouse illustrating colocalization of ubiquitin staining with PS129-a-synuclein-positive deposits (top panel). Note that ubiquitin was present in most of
the swollen PS129-a-synuclein-positive neurites (arrows). Synphilin-1-immunoreactivity was not found within the PS129-a-synuclein-positive deposits
(middle panel), whereas it was detected in nerve processes in a representative region of the cerebellum (lower panel). gr: granular cell layer; P:
Purkinje cell layer; mol: molecular cell layer. Scale bars indicate 25 mm. (B) Percentage of PS129-a-synuclein-immunopositive neurites and cell bodies
co-labelled for ubiquitin in a representative region of the brainstem of symptomatic hA30Pa-syn mice with or without Parkin (n = 4–5). *, p,0.05.
doi:10.1371/journal.pone.0006629.g006
PARK2 Modifies Synucleinopathy
PLoS ONE | www.plosone.org 7 August 2009 | Volume 4 | Issue 8 | e6629
substrate, a-tubulin, but not with PS129-a-synuclein when added to
brain extracts from symptomatic hA30Pa-syn mice (Figure 7A). In
addition, GST-Parkin was unable to promote the ubiquitylation of
recombinant, phosphorylated human a-synuclein in a purely in
vitro ubiquitylation assay (Figure 7B).
PS129a-synuclein-immunoreactivity is associated with
caspase 9 activation in hA30Pa-syn transgenic mice
Whether there is a causative relationship between PS129-a-
synuclein accumulation and the pathogenesis of synucleinopathies
is currently a matter of debate [40,41–44]. In diseased hA30Pa-
syn mice, many PS129-a-synuclein-positive neuronal cell bodies
were abnormally shaped, with dysmorphic nuclei or aberrantly
swollen cytoplasm and proximal neurites, whether or not they
accumulated ubiquitin (Figure 8A). Cleaved capase 9 immunore-
activity has been reported in viral vector-based models of
synucleinopathy [44,45], so we evaluated activation of caspase 9
in end-stage hA30Pa-syn mice (Figure 8B). Cleaved caspase 9 was
found in approximately 5% of the neuronal cell bodies
accumulating PS129-a-synuclein in the spinal cords of transgenic
mice (7.461.8% with and 4.5%62.2 without Parkin; p = 0.4), and
in a similar proportion of cell bodies of neurons accumulating both
PS129-a-synuclein and ubiquitin (6.3%62.8 in the presence of
Parkin, 6.7%62.9 in its absence; p = 0.9). Importantly, deposits of
PS129-a-synuclein were present in more than 90% of the neurons
in which caspase 9 was activated in hA30Pa-syn mice both with
(92.0%63.2) and without Parkin (96.0%63.1; p = 0. 4).
Discussion
We report an investigation of the effects of Parkin deficiency on
the pathological accumulation of the A30P variant of human a-
synuclein and the manifestation of the neurodegenerative
phenotype in a transgenic mouse model of synucleinopathy
(hA30Pa-syn mice) [14]. Disease onset in hA30Pa-syn mice was
preceded by specific, progressive impairment of performance in
two tasks —hindlimb extension reflex and rotarod tests—
predictive of neuronal dysfunction in sensorimotor nuclei of the
brainstem and the spinal cord. Disease progression was accom-
panied by the specific deposition of insoluble PS129-a-synuclein
species, detected by biochemical and immunohistochemical
methods throughout the brainstem and the spinal cord. In
contrast, PS87-a-synuclein immunoreactive species readily detected
Figure 7. Phosphorylated a-synuclein is not a Parkin substrate. Analysis of a representative GST-pull-down assay performed by incubating
GST-Parkin [26] or GST with the TBS-soluble protein fraction from a symptomatic hA30Pa-syn mouse. Antibodies against human a-synuclein, PS129-a-
synuclein or a-tubulin were used for western blotting. GST-Parkin interacts specifically with a-tubulin [54], but not with a-synuclein or PS129-a-
synuclein. The asterisk indicates the GST-moiety resulting from the degradation of the proteolytically unstable recombinant GST-Parkin protein. (B)
Results of an in vitro ubiquitylation assay performed by incubating GST-Parkin, or the enzymatically inactive GST-ParkinC418R variant, with ubiquitin-
activating enzyme, ubiquitin-conjugating enzyme, UbcH7, FLAG-tagged ubiquitin and ATP, in the presence or absence of in vitro-phosphorylated a-
synuclein (PS87,129-a-syn). Once the reaction was completed, GST-Parkin was immobilized on glutathione-sepharose beads; the beads and the
supernatant fraction were analyzed by western blotting with anti-FLAG, PS129-a-synuclein, or anti-Parkin antibodies. GST-Parkin (but not GST-
ParkinC418R) promoted its own ubiquitylation in a dose-dependent manner, as demonstrated by the amounts of ubiquitylated species in the bead
fraction being proportional to the amounts of GST-Parkin used for the ubiquitylation reactions. In addition, GST-Parkin (but not GST-ParkinC418R)
promoted the formation of ubiquitin chains, as indicated by the presence of a ladder of regularly spaced ubiquitin-immunoreactive protein bands in
the supernatant fraction. However, GST-Parkin did not promote the ubiquitylation of PS129-a-synuclein: PS129-a-synuclein-immunoreactive proteins
with higher apparent molecular mass than the monomer were not detected in the supernatant fraction at any of the GST-Parkin concentrations used
in the assay (PS129-a-syn); moreover, we did not observe any ubiquitin-immunoreactive bands specific for PS129-a-synuclein in the supernatant
fraction (FLAG). The asterisk indicates a FLAG immunoreactive band most likely corresponding to a thioester adduct formed between the E2 enzyme
UbcH7 and FLAG-tagged ubiquitin in the presence of the E1 enzyme.
doi:10.1371/journal.pone.0006629.g007
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in the soluble brain fractions were not deposited as insoluble
material in diseased hA30Pa-syn mice. Previous reports failed to
identify PS87-a-synuclein-immunoreactive species by biochemical
or immunohistochemical techniques in mouse models overpro-
ducing human a-synuclein and in brains from synucleinopathy
patients, suggesting that PS87-a-synuclein is not involved in the
physiopathology of neurodegenerative disorders associated with a-
synuclein accumulation [2,46]. Whether there is a causative
relationship between PSer129-a-synuclein accumulation and the
pathogenesis of synucleinopathies is a matter of controversy which
still needs to be clarified [40,41,43,44]. In our model, immuno-
reactivity to active caspase 9 was observed in 5–10% of the PS129-
a-synuclein-positive neuronal cell bodies of the spinal cord, and
was almost exclusively associated with the presence of deposited
PS129-a-synuclein, indicating that accumulation of this protein
may be a deleterious event related to neurodegeneration. As in
human synucleinopathies [2–4,47], some of the PS129-a-synuclein
deposits were associated with ubiquitin, suggesting that ubiquityla-
tion is a secondary event following protein deposition.
In late-stage symptomatic mice, the disease-specific neuropath-
ological features were similar in the presence and absence of
Parkin. However, the proportion of PS129-a-synuclein-immunore-
active deposits associated with ubiquitin was lower, indicating less
advanced a-synucleinopathy. Moreover, in the absence of Parkin,
the mean decline in sensorimotor performance and the manifes-
tation of disease were significantly delayed in hA30Pa-syn mice.
These results are in apparent contradiction with previous studies
reporting that Parkin protects against a-synuclein-mediated
toxicity in primary neurons, in Drosophila and in rats [32–35].
However, Parkin was overproduced beyond physiological levels in
these models. In addition, cell survival was only monitored in the
short-term, raising the possibility that Parkin modulate synucleino-
pathy with distinct short-term and long-term effects on neuronal
viability. When overproduced in the rat substantia nigra together
with A30P a-synuclein by lentiviral vector-mediated gene transfer,
Parkin protected dopaminergic neurons from degeneration six
weeks after inoculation of the vectors [35]. Neuroprotection was
accompanied by an increase in the proportion of neurons carrying
PS129-a-synuclein-positive aggregates, suggesting that Parkin
promotes the deposition of this protein. Other studies have shown
that overproduced Parkin promotes the formation of ubiquitylated
aggregates, providing in some cases protection against the toxicity
of the involved proteins, perhaps by sequestering diffusible toxic
species [20,24,48]; in the long term, this process could contribute
to neuronal dysfunction and accelerate neurodegeneration.
However, Parkin did not bind to PS129-a-synuclein in brain
extracts from hA30Pa-syn mice, and it was unable to promote the
ubiquitylation of phosphorylated a-synuclein in vitro. It is therefore
unlikely that endogenous Parkin contributes to the deposition of
PS129-a-synuclein through direct mechanisms.
Compensatory mechanisms triggered by Parkin deficiency may
intervene indirectly in delaying synucleinopathy and neurodegen-
eration in hA30Pa-syn mice. Elevated levels of reduced glutathi-
one have been reported throughout the brain of Parkin-deficient
mice. Interestingly, overexpression of genes involved in glutathi-
one biosynthesis and conjugation have each been recently shown
to protect against neurodegeneration in a Drosophila model of
synucleinopathy [49]. Although the link between increased
glutathione levels and decreased a-synuclein toxicity in this model
remains to be established, it is plausible that increased antioxidant
activities associated with the established role of glutathione in
protection against oxidative stress [50] affect a-synuclein aggre-
gation. It would be valuable to determine the relative contribution
of parkin to the molecular pathway leading to accumulation of a-
synuclein and neurodegeneration in hA30Pa-syn mice. Current
studies in our laboratory aim at evaluating whether and to what
extent the deletion of a single parkin allele affects the delay in
appearance of signs of motor dysfunction and disease manifesta-
tion in this model. These studies should provide useful clues to the
mechanisms underlying our current observations; gene dosage-
dependent effects would be indicative of direct genetic interaction
between parkin and SCNA, whereas their absence would rather hint
at compensatory neuroprotective mechanisms triggered by
complete but not partial Parkin depletion.
The effects of Parkin deficiency has been studied in a transgenic
mouse model overproducing the A53T variant of human a-
synuclein. These mice displayed a neurodegenerative phenotype
similar to that observed in hA30Pa-syn mice, but with more severe
progression: by 12 months of age, 50% of the hA53Ta-syn mice
were affected [51], whereas at this age, none of the hA30Pa-syn
mice in our study presented features of disease. As in our model,
the absence of Parkin did not affect the amount or distribution of
native a-synuclein, or the appearance of ubiquitin-positive profiles;
unfortunately, PS129-a-synuclein accumulation was not studied.
Although a longitudinal analysis of motor performance in
hA53Ta-syn mice was not provided, the survival curves with
and without Parkin were similar. The differences between our
results and those described by von Coelln et al may indicate that
Parkin deficiency affects A53T and A30P a-synucleinopathies
Figure 8. PS129-a-synuclein-immunoreactivity is associated
with activation of caspase 9. (A) Examples of PS129-a-synuclein-
positive neurons with abnormally shaped nuclei and dysmorphic or
abnormally swollen somata and proximal dendrites in the brainstem of
symptomatic hA30Pa-syn mice. The upper and lower right micrographs
correspond to a higher magnification of the regions outlined by the
frames in the left micrograph. (B) Double immunofluorescent labelling
showing caspase 9 activation in representative PS129-a-synuclein- or
ubiquitin-positive neurons of the spinal cord. Scale bars indicate 30 mm
in (A) and 15 mm in (B).
doi:10.1371/journal.pone.0006629.g008
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differently; Parkin deficiency may have a smaller effect on A53T
a-synuclein-induced neurodegeneration due to the higher intrinsic
aggregation potential [52] and toxicity of A53T a-synuclein than
A30P a-synuclein, leading to a more rapidly progressive
neurodegenerative phenotype in mice [15,51].
Unfortunately, neither hA53Ta-syn [51] nor hA30Pa-syn mice
provided evidence for interaction between Parkin deficiency and
synucleinopathy in catecholaminergic brainstem neurons (Figure
S2, Table S1). This may be due to the weakness of the promoters
used to drive transgene expression in these neuronal populations
(Results S1, Figure S1B). Therefore, further work with models in
which a-synuclein accumulates abundantly in the dopaminergic
neurons of the substantia nigra, e.g. through viral vector-mediated
gene transfer, is required to confirm our findings.
In conclusion, we provide unprecedented evidence that Parkin
deficiency modulates the phenotypic expression of disease in a
long-term mouse model of synucleinopathy. These findings raise
the intriguing possibility that the loss of functional Parkin is a
beneficial modifier of a-synuclein build-up in the slowly progres-
sive parkin-related parkinsonian syndromes, in which LB pathology
is more rarely observed and less severe than in sporadic PD [30].
Materials and Methods
Ethics Statement
All experiments involving mice were approved by the Ile de
France Regional Ethics Committee for Animal Experiments, Nu3
(P3/2006/006).
Generation of transgenic mice overproducing human
A30P a-synuclein in a Parkin-deficient background
Mice transgenic for human A30P a-synuclein and deficient for
Parkin were generated by a crossbreeding strategy aimed at
minimising potential strain effects, using two previously established
mouse lines: parkin exon 3-deleted mice (parkin 2/2) [36], brought
into the C57Bl/6j genetic background by an accelerated backcross
procedure; and hA30Pa-syn mice (line 31H) [14,37], brought into
a C57Bl/6j background by eight consecutive backcrosses
(Figure 1A). Homozygous parkin 2/2 mice were bred with
homozygous hA30Pa-syn mice and mice of the double heterozy-
gous generation were then intercrossed. The progeny of this
intercross was genotyped by PCR amplification. Genomic DNA
was prepared from tail fragments homogenized in lysis buffer
(100 mM Tris-HCl, 0.2% SDS, 200 mM NaCl, 1 mM CaCl2)
and digested with proteinase K (10 mg/ml) overnight at 55uC; the
DNA was precipitated with isopropanol (v/v) and rinsed with 70%
ethanol. The parkin genotype was determined by two parallel
PCRs using sets of oligonucleotide primers specific for the parkin
gene (Fwt: 59-TGCTCTGGGGTTCGT C-39; Rwt: 59-
TCCACTGGCAGAGTAAATGT-39) and for the recombinant
knock-out allele (FKO: 59-TTGTTTTGCCAAGTTCTAAT-39;
RKO: -TCCACTGGCAGAGTAAATGT-39). PCR amplification
was carried out in 25 ml reaction mixes containing approximately
300 ng of genomic DNA, 2 mM MgCl2, 0.2 mM dNTPs, 0.4 mM
of each oligonucleotide and 1U Taq polymerase (Abscys) in 1X
PCR buffer (Abscys). After an initial denaturation step of 3 min at
94uC, PCR conditions were: 35 cycles of 94uC, 30 s; 58uC, 30 s;
72uC, 40 s; followed by a 10 min extension at 72uC. Semi-
quantitative real-time PCR was performed with genomic DNA
and an ABI Prism 7700SDS instrument, to determine whether the
hA30Pa-syn transgene was present in the heterozygous or
homozygous state. The oligonucleotide pair used to amplify the
human transgene was: F: 59-AGGGAGCAGGGAGCATTG -39;
R: 59-CAGGATCCACAGGCATATC-39. The amplification was
carried out in reaction volumes of 25 ml consisting of SYBR Green
PCR Universal Master Mix (Applied Biosystems) containing 1 ng
of DNA and 0.8 mM of each oligonucleotide. The reactions were
incubated for 2 min at 50uC and for 10 min at 95uC, and then
amplifications were performed as follows: 40 cycles of 95uC, 10 s;
60uC, 60 s. Values for the hA30Pa-syn transgene were normalized
to those obtained in the same amplification conditions for the
endogenous glyceraldehyde-3-phosphate dehydrogenase gene with
the oligonucleotides F: 59-GAACATCATCCCTGCATCCA-39
and R: 59-CCAGTGAGCTTCCCGTTCA-39. Western blotting
was used to examine the expression of the endogenous parkin gene
and of the hA30Pa-syn transgene in hemi-brains from four 17
months-old asymptomatic mice per genotype, as described below.
The frequencies of the nine genotypes of the progeny of the
double heterozygous intercross were consistent with Mendelian
inheritance. Double homozygous mice and their age-matched
littermates of wild-type or single-homozygous, parental genotypes
were collected for subsequent analyses. After weaning, male and
female mice were separated and maintained at a maximum of five
littermates per cage, with food and water ad libitum, and at constant
temperature (21uC) with a 07:00 – 19:00 light cycle.
Behavioural analyses
The behaviour of age-matched littermate mice (females) of each
selected genotype (n = 10–16) was tested every week, from 9 to 24
months of age. To limit sources of variability, including
unnecessary stress, the conditions for testing were kept as constant
as possible: the mice were hosted and tested in the same room; the
same experimenters (MF and JG), blind to the genotype of the
animals throughout the testing period, took care of them and
assessed their performance weekly on two consecutive days
(Tuesday and Wednesday morning); the tasks were performed in
the same order ((i) extension reflex, (ii) rotarod); the between-cage
order of testing, initially chosen at random, was kept constant
throughout the testing period. Since mice of the same litter were
grouped into cages, each cage hosted age-matched animals of
different genotypes; the within-cage order of testing was random.
Each behavioural session was held during the light period,
between 9 a.m. and 12 a.m. and included the two following tests:
Rotarod — The time spent on a rod (Columbus Instrument)
rotating at a speed of 12 rpm was measured. The test was stopped
after an arbitrary period of 180 s. Mice falling before the end of
this period were tested a second time, and the best trial (longest
time) was recorded.
Hindlimb extension reflex — Mice were suspended by their tail
and the extension reflex of their hindlimbs was observed. The
attribution of arbitrary extension scores was adapted from [38] as
follows: 2 for normal extension of both hindlimbs; 1.5 for
incomplete extension of one hindlimb; 1 for absence of extension
of one hindlimb; 0.5 for absence of extension of one hindlimb and
incomplete extension of the second limb; 0 for absence of
extension of both hindlimbs.
Western-blot analysis, GST pull-down and in vitro
ubiquitylation assays
Brain extracts were fractionated as described [53]. Briefly,
posterior hemi-brains (from bregma -2; approximately 150 mg of
frozen tissue) were homogenized in TBS (Tris-buffered saline)
containing protease (Complete protease inhibitor cocktail, Roche
Diagnostics) and phosphatase (30 mM NaF, 30 mM b-glycero-
phosphate, 0.2 mM Na3VO4, 5 mM Na-pyrophosphate and
30 nM okadaic acid) inhibitors. The samples were sonicated,
centrifuged at low speed (1,0006g, 5 min, 4uC) and ultracentri-
fuged (130,0006g, 1 h, 4uC). The resulting supernatants (the TBS-
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soluble fractions) were collected. The pellets were extracted twice
with 200 ml of TBS containing 5% SDS, and the resulting
supernatants were collected and pooled as the TBS-insoluble
(SDS-soluble) fraction. Protein concentrations were determined
using the bicucullinic acid (BCA) protein assay (Pierce). To
confirm genotypes (Figure 1), TBS-soluble brain fractions (10 mg)
from non symptomatic 17 months-old mice were analyzed. TBS-
and SDS-soluble brain fractions (30 mg) from 17 months-old non
symptomatic and 17–25 months-old symptomatic mice were used
for assaying a-synuclein and PS129-a-synuclein proteins (Figure 7).
GST pull-down assays were done as described previously [26],
with 500 mg TBS-soluble brain fraction from a symptomatic
mouse, and 5 mg of GST or GST-Parkin immobilized on
glutathion-sepharose beads (Amersham Biosciences). Ubiquityla-
tion assays were carried out as described in [26]. Recombinant
normal a-synuclein and the S87A and S129A variants were
produced, purified and phosphorylated in vitro as described
previously [42].
Proteins were resolved by SDS-PAGE on 4–12% gradient gels
(Invitrogen). The proteins were electrotransferred onto nitrocellu-
lose membranes and probed with: monoclonal anti-Parkin
(MAB5512, clone PRK8, Chemicon), anti PS129-a-synuclein
(clone PSyn#64, WAKO; clone EP1536Y, Abcam), anti-a-tubulin
(clone DM 1A, Sigma), anti-FLAG (M2, Sigma); polyclonal anti-a-
synuclein (SA3400, Affiniti) and anti-actin (A2066, Sigma), anti-
GST (GE Healthcare/Amersham). Proteins were visualized by
enhanced chemioluminescence (Pierce) using a Kodak Image
Station 4000 MM. The Image J program (http://rsb.info.nih.
gov/ij/) was used for signal quantification.
Immunohistochemistry
Mice were anaesthetized with pentobarbital (130 mg/kg, i.p.;
Sigma, St Quentin, France) and perfused transcardially with 4%
paraformaldehyde freshly prepared in 0.1 M PBS, pH 7.4. Brains
were removed and post-fixed for two hours in the same solution.
Left-half brains were dehydrated by four 10 min incubations and
two 20 min incubations in ethanol at 35uC, followed by three
incubations of 45, 60 and 75 min each in xylene, at 35uC. The
tissues were then embedded in paraffin by three incubations of 40,
15 and 15 min each at 65uC (Shandon Excelsior tissue processor
from Thermo Scientific) and cut on a microtome into 5 mm-thick
sections collected on slides and stored at room temperature. For
immunohistochemistry, sections were deparaffinized in xylene,
and hydrated in a descending series of ethanol concentrations.
Antigens were retrieved by boiling the sections in 0.01 M citrate
buffer, pH 6.0, five times for 3 min in a microwave at 350 Watts.
For immunoperoxidase staining, sections (5 and 20 mm thick)
were incubated in PBS containing 3% H2O2 and 20% ethanol for
5 min, to inhibit endogenous peroxidases. Sections were permea-
bilized and non specific epitopes were blocked by incubation for
45 min in PBS containing: 2% BSA, 0.1% Triton X-100 (tyrosine-
hydroxylase (TH)-staining); 2% NGS, 5% BSA, 0.1% Triton X-
100 (PS129-a-synuclein staining); or 20% newborn goat serum,
10% BSA, 0.1% Triton X-100 (ubiquitin staining and double
immunofluorescent labelling). Sections were hybridized overnight
at 4uC with the primary antibodies, then treated with biotinylated
secondary anti-rabbit IgG antibody (Vectastain; Vector Labora-
tories, Burlingame, CA, USA), and incubated with avidin and
biotinylated horseradish peroxidase complex. The signal was
revealed by incubating the sections in 0.25 M Tris-HCl, pH 7.4
containing 0.5% of the peroxidase substrate, 3,39-diaminobenzi-
dine tetrahydrochloride, and 0.015% H2O2. The sections were
dehydrated in an ascending series of ethanol concentrations,
cleared in xylene, and mounted with Eukitt Mounting Medium.
For immunofluorescent staining, the sections were then
incubated with the primary antibody overnight, at 4uC and the
signal revealed by incubation with Alexa Fluor 488-coupled goat
anti-rabbit IgG antibody (1:2000, Invitrogen) or Cy3-coupled
donkey anti-mouse IgG antibody (1:200, Jackson), for one hour at
room temperature. The same procedure was used twice
sequentially for double stainings. Fluorescent images were
acquired with an epifluorescensce microscope (Axioplan 2, Zeiss,
Germany) equipped with the FluoUp image analysis system
(Explora Nova, La Rochelle, France).
Primary antibodies were: rabbit polyclonal anti-PS129-a-synu-
clein (1:500, kindly provided by T. Iwatsubo [1]); anti-ubiquitin
(1:1500, DAKO); anti-synphilin-1 (1:150, kindly provided by
Simone Engelender); and anti-activated caspase 9 (1:200, Cell
Signalling); rabbit monoclonal anti-PS129-a-synuclein (1:5000,
Abcam); mouse monoclonal anti-PS129-a-synuclein (1:1500,
WAKO); and anti-ubiquitin (1:500, Chemicon). Anti-PS87-a-
synuclein antibodies were raised in rabbits against a peptide
identical to residues 81–93 of human a-synuclein, with serine 87
being phosphorylated (Eurogentec), and used at a 1:100 dilution.
Immunostainings for total human a-synuclein and TH were
done as described in Materials and Methods S1.
Quantitative immunohistochemical analyses
The density of PS129-a-synuclein immunostaining was evaluated
in symptomatic mice (n = 5 per genotype) by determining the
mean of eight 5 mm-thick coronal hemi-brain, blind-coded
sections, 120 mm apart, covering a brainstem region between
bregma 22.5 and 23.5 mm, with a 256objective and using the
Mercator workstation. The borders of the brainstem area on each
section were drawn manually and a grid with counting frames of
1506150 mm was superimposed onto the region of interest. The
number of intersections between immunolabelled structures and
grid lines was registered for each section. The mean staining
density was defined as the average number of intersections per
section. TH-positive neurons in the substantia nigra and the locus
coeruleus were quantified as described in Materials and Methods S1
and in Reference S1.
Colocalization between PS129-a-synuclein and ubiquitin was
analyzed in spinal cord sections processed for double immunoflu-
orescent staining. Images of at least five double-immunostained
neurites and five cell bodies from three animals per genotype were
taken with a confocal microscope (Leica SP2 AOBS). Colocaliza-
tion was evaluated with the Pearson’s coefficient calculated with
the ‘‘Colocalization Threshold’’ plugin of the Java image
processing program Image J (http://rsb.info.nih.gov/ij/). The
proportion of PS129-a-synuclein-positive cell bodies and neurites
immunopositive for ubiquitin was determined from one or two
representative double immunofluorescence-labelled, 5 mm-thick
brainstem sections from symptomatic mice, chosen between
bregma 22.5 and 23.5 mm according to the abundance of
immunolabelled structures. To determine the proportion of PS129-
a-synuclein-positive neurites co-stained with anti-ubiquitin anti-
bodies, fluorescent images were acquired with an epifuorescence
microscope (Axioplan 2, Zeiss, Germany), with a filter set for
Alexa Fluor 488 (PS129-a-synuclein) and a filter set for Cy3
(ubiquitin), and a 636objective; 30 to 130 PS129-a-synuclein-
positive neurites were scored per animal (n = 5 per genotype). To
determine the proportion of double-labelled cell bodies, brain
sections were examined directly with the epifluorescent micro-
scope and the 636objective; 30 to 200 PS129-a-synuclein-positive
cell bodies were scored per animal (n = 4 per genotype).
The percentage of PS129-a-synuclein- or ubiquitin-positive
neurons double stained for cleaved caspase 9, and the percentage
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of neurons accumulating cleaved caspase 9 co-labelled for PS129-a-
synuclein or ubiquitin was estimated throughout the spinal cord of
symptomatic mice. Sections were examined directly with the
epifluorescent microscope and the 636objective; 140 to 660
neuronal cell bodies with PS129-a-synuclein, and 30 to 330 with
ubiquitin staining were scored per animal (n = 4 per genotype).
Seventy neurons with cleaved caspase 9 staining were scored for
hA30Pa-syn mice without Parkin (n = 4), and 150 for hA30Pa-syn
mice with Parkin (n = 4).
Statistical analyses
Values from behavioural studies were analyzed using second-
order polynomial curve fitting of mean performance against age,
and ANOVA comparison of the corresponding regression curve
parameters (slope and curvature), with genotype as qualitative
factor. The regression equations were:
1ð Þ Extension reflex :
-wild-type : Extension score
~{0:00002Age2z0:003Agez1:87,
-parkin{={ : Extension score :
{0:0000006Age2{ 0:00005Agez 1:95,
-hA30Pa{synz=z : Extension score
~{ 0:0006Age2z 0:06Agez 0:61
-parkin{={; hA30Pa{synz=z : Extension score
~{ 0:0003Age2z 0:03Agez 0:93;
2ð Þ Rotarod
-wild-type : Time on rod
~ 0:016Age2{ 2:31Agez 246:21,
-parkin{={ : Time on rod
~{ 0:0005Age2z 0:08Agez 176:26,
-hA30Pa{synz=z : Time on rod
~{ 0:08Age2z 8:81Age{ 66,60,
-parkin{={; hA30Pa{synz=z : Time on rod
~{ 0:051Age2z 6:56Age{32:75:
Unpaired t-tests were used to estimate differences in disease
progression between groups. Data from quantitative western blots
were analyzed using two-way ANOVA, followed by the Student-
Newman-Keuls Method for pairwise multiple comparisons, as
appropriate. An unpaired two-tailed t-test was used to estimate
differences in the percentages of PS129-a-synuclein- or ubiquitin-
positive neurons with cleaved caspase 9 staining between
symptomatic hA30Pa-syn littermate mice with and without
Parkin. An unpaired one-tailed t-test was used to analyse the
proportion of PS129-a-synuclein-positive structures co-labelled with
anti-ubiquitin antibodies.
Supporting Information
Results S1
Found at: doi:10.1371/journal.pone.0006629.s001 (0.03 MB
DOC)
Materials and Methods S1
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Figure S1 Thy-1-driven expression of the hA30PIˆ6-syn trans-
gene throughout the brain and spinal cord of aged mice. A,
Representative micrographs showing immunohistochemical label-
ling of human Iˆ6-synuclein in various brain and spinal cord
regions from healthy hA30PIˆ6-syn 17 months-old mice (a–f), and
from end-stage symptomatic mice presenting pathological profiles
(arrows) (g–i). Both typical, dotted synaptic labelling and staining
of the somatodendritic compartment were observed. Similar
results were obtained in the presence or absence of Parkin. Scale
bar: 100 IˆJm. B, Iˆ6-Synuclein immunoreactivity is absent from
the cell bodies of monoaminergic neurons of the substantia nigra
and the locus coeruleus. Representative micrographs of confocal
laser-scanned brain sections from 17 months-old hA30PIˆ6-syn
mice, immunolabelled by double fluorescence with anti-human
Iˆ6-synuclein and anti-TH antibodies. Arrows and arrowheads
indicate TH- and human Iˆ6-synuclein-immunopositive neurons,
respectively. Similar results were obtained in the presence and
absence of Parkin. Scale bar: 50 Aˆmm.
Found at: doi:10.1371/journal.pone.0006629.s005 (11.19 MB
TIF)
Figure S2 Parkin deficiency does not affect the survival of the
dopaminergic neurons of the SNc in 17 months-old hA30PIˆ6-syn
mice. A, Micrographs illustrating TH-immunoreactivity in the
substantia nigra of mice representative of each genotype. B,
Stereological quantification of TH-positive neurons in the
substantia nigra pars compacta (n = 4). Data presented are
means6SEM. Scale bar: 100 Aˆmm.
Found at: doi:10.1371/journal.pone.0006629.s006 (6.69 MB TIF)
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